← Back

Palisade Bio Inc

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company that develops oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead product candidate, PALI-2108, is in a Phase 1b clinical trial for inflammatory bowel disease, including ulcerative colitis and fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds, a license agreement with the Regents of the University of California for the sole purpose of maintaining the Newsoara Co-Development, and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Founded in 2001, Palisade Bio is headquartered in Denver, Colorado.

Price · split & dividend adjusted
News & notes moving PALI
PALI▼

Palisade Bio Q2 net loss widens to $10.6 million, Phase 2 ASCENTRA-UC trial enrollment set for H2 2026

Palisade Bio reported a second-quarter net loss of $10.6 million, up from $2.8 million a year earlier, while loss per share narrowed to $0.05 from $0.58. The company recorded $0.5 million in licensing revenue from a milestone payment under a distribution agreement with Newsoara, a joint venture established by Biolead Medical Technology Limited. Cash and equivalents stood at $125.2 million as of June 30, 2026, expected to fund operations into early 2028. The Phase 2 ASCENTRA-UC trial of lead candidate PALI-2108 for ulcerative colitis is planned to begin enrollment in the second half of 2026, with primary efficacy data anticipated in the second half of 2027. For Crohn’s disease, an IND submission for the ASCENTRA-CD study is expected in the second half of 2026, with trial commencement in the first quarter of 2027 and primary efficacy readout in early 2028. Shares fell 3.33% in overnight trading to $2.03.
PALI ▼
RTTNews·38dRead more →
Biotech & Genomic Medicine▲

Palisade Bio Gets FDA Clearance for PALI-2108, Plans Phase 2 Ulcerative Colitis Trial

Palisade Bio has received FDA clearance of its Investigational New Drug application for PALI-2108, allowing the company to begin a global Phase 2 trial in ulcerative colitis. The ASCENTRA-UC study is expected to enroll up to 204 patients with moderately to severely active disease across North America and Europe, with first enrollment anticipated in the second half of 2026 and primary efficacy results expected in the second half of 2027. The trial will evaluate two once-daily doses of PALI-2108, 15 mg and 30 mg, against placebo, with clinical remission at Week 12 as the primary endpoint. Palisade Bio has partnered with contract research organization PSI to manage the program and also plans to submit an IND for a Crohn's disease trial in the second half of 2026.
PALI ▲
Biotech & Genomic Medicine
GlobeNewswire·81dRead more →
© 2026 MarketDXAsset